The Metabolic Syndrome

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 1, Issue , 2010, Pages 822-839

  Ruderman, Neil ^a,b   Shulman, Gerald I ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85153818507     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00044-7     Document Type: Chapter

References (273)

1. RH Eckel, SM Grundy and PZ Zimmet (2005) The metabolic syndrome. Lancet 365 1415-1428.
2. G Reaven (2002) Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106 286-288.
3. E Richter and N Ruderman (2009) AMPK and the biochemistry of exercise: implications for human health and disease. The Biochemical Journal in press
4. AH Kissebah, N Vydelingum, R Murray, et al. (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54 254-260.
5. RS Bernstein, N Grant and DM Kipnis (1975) Hyperinsulinemia and enlarged adipocytes in patients with endogenous hyperlipoproteinemia without obesity or diabetes mellitus. Diabetes 24 207-213.
6. NB Ruderman, SH Schneider and P Berchtold (1981) The “metabolically-obese,” normal-weight individual. Am J Clin Nutr 34 1617-1621.
7. KF Petersen, S Dufour, D Befroy, et al. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 664-671.
8. N Ruderman, D Chisholm, X Pi-Sunyer, et al. (1998) The metabolically obese, normal-weight individual revisited. Diabetes 47 699-713.
9. A Festa, R D'Agostino Jr, G Howard, et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 42-47.
10. JC Pickup (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 813-823.
11. MI Schmidt, BB Duncan, AR Sharrett, et al. (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353 1649-1652.
12. I Juhan-Vague, MC Alessi and P Vague (1991) Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34 457-462.
13. P Sakkinen, D Geffken, M Cushman, et al. (2001) Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 153 242-250.
14. GM Reaven (2003) Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88 2399-2403.
15. SM Grundy, JI Cleeman, SR Daniels, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 2735-2752.
16. ES Ford, WH Giles and WH Dietz (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 356-359.
17. SM Grundy (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28 629-636.
18. G Alberti, P Zimmet, J Shaw, et al. (2004) Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 27 1798-1811.
19. R Weiss, S Dufour, SE Taksali, et al. (2003) Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362 951-957.
20. R Weiss, J Dziura, TS Burgert, et al. (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 2362-2374.
21. GM Reaven (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 1595-1607.
22. SM Grundy (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92 399-404.
23. R Kahn, J Buse, E Ferrannini, et al. (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 2289-2304.
24. B Viollet, R Mounier, J Leclerc, et al. (2007) Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33 395-402.
25. P Dieterle, H Fehm, W Stroder, et al. (1968) Asymptomatic diabetes mellitus in hypertensive patients of normal weight. Glucose tolerance and serum levels of insulin and nonesterified fatty acids in essential hypertension. Ger Med Mon 13 478-483.
26. M Modan, H Halkin, S Almog, et al. (1985) Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75 809-817.
27. MP Stern (1997) The insulin resistance syndrome. KGMM Alberti,(Eds) International Textbook of Diabetes Mellitus New York: John Wiley & Sons Ltd. 255-283.
28. JS Flier (1993) An overview of insulin resistance. DE Moller,(Eds) Insulin Resistance Chichester, U.K.: Wiley 1-8.
29. H Himsworth (1936) Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1 127.
30. HP Himsworth and RB Kerr (1939) Insulin sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 4 119-152.
31. HP Himsworth (1949) The syndrome of diabetes mellitus and its causes. Lancet 1 465-473.
32. RS Yalow and SA Berson (1960) Immunoassay of endogenous plasma insulin in man. J Clin Invest 39 1157-1175.
33. SA Berson and RS Yalow (1961) Plasma insulin in health and disease. Am J Med 31 874-881.
34. JH Karam, GM Grodsky and PH Forsham (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12 197-204.
35. P Bjorntorp (1997) The relationship between obesity and diabetes. KGMM Alberti,(Eds) International Textbook of Diabetes Mellitus New York: John Wiley & Sons Ltd. 612-627.
36. PC Davidson and MJ Albrink (1965) Insulin resistance in hyperglyceridemia. Metabolism 14 1059-1070.
37. RA DeFronzo and E Ferrannini (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 173-194.
38. C Malherbe, F Heller, M de Gasparo, et al. (1970) Insulin response during prolonged glucose infusion. J Clin Endocrinol Metab 30 535-538.
39. NB Ruderman, P Berchtold and S Schneider (1982) Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes 6(Suppl 1), 151-157.
40. NB Ruderman and C Haudenschild (1984) Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26 373-412.
41. KF Petersen, S Dufour, J Feng, et al. (2006) Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 103 18273-18277.
42. H Bays, L Mandarino and RA DeFronzo (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89 463-478.
43. L Lapidus, C Bengtsson, B Larsson, et al. (1984) Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 289 1257-1261.
44. B Larsson, K Svardsudd, L Welin, et al. (1984) Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death:13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 288 1401-1404.
45. H Beck-Nielsen and LC Groop (1994) Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94 1714-1721.
46. G Perseghin, TB Price, KF Petersen, et al. (1996) Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 335 1357-1362.
47. DL Rothman, I Magnusson, G Cline, et al. (1995) Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 92 983-987.
48. P Ferrari, P Weidmann, S Shaw, et al. (1991) Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 91 589-596.
49. NB Ruderman, SH Schneider and P Berchtold (1981) The “metabolically-obese,” normal-weight individual. Am J Clin Nutr 34 1617-1621.
50. B Werbin, I Tamir, D Heldenberg, et al. (1977) Immunoreactive insulin and glucose response to oral glucose in offspring of patients with endogenous hypertriglyceridaemia. Clin Chim Acta 76 35-40.
51. JP Despres, B Lamarche, P Mauriege, et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 952-957.
52. P Ducimetiere, E Eschwege, L Papoz, et al. (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19 205-210.
53. K Pyorala (1979) Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2 131-141.
54. TA Welborn and K Wearne (1979) Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2 154-160.
55. RW Nesto, RT Phillips, KG Kett, et al. (1988) Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 108 170-175.
56. UKPDS (1990) Complications of newly diagnosed type 2 diabetes patients and their association with different clinical and biochemical risk factors. Diab Res 13 1-11.
57. MI Uusitupa, LK Niskanen, O Siitonen, et al. (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36 1175-1184.
58. RJ Jarrett, P McCartney and H Keen (1982) The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 22 79-84.
59. SM Haffner, MP Stern, HP Hazuda, et al. (1990) Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263 2893-2898.
60. C Panzer, A Brieke and NB Ruderman (2003) Prevention of type 2 diabetes and its macrovascular complications: whom, when and how should we treat? Current Opinions in Endocrinology and Diabetes 10 219-236.
61. WC Knowler, E Barrett-Connor, SE Fowler, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 393-403.
62. XR Pan, GW Li, YH Hu, et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance, The Da Qing IGT and Diabetes Study. Diabetes Care 20 537-544.
63. J Tuomilehto, J Lindstrom, JG Eriksson, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 1343-1350.
64. TA Buchanan, AH Xiang, RK Peters, et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 2796-2803.
65. HC Gerstein, S Yusuf, J Bosch, et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 1096-1105.
66. BA Neuschwander-Tetri, EM Brunt, KR Wehmeier, et al. (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 1008-1017.
67. BA Neuschwander-Tetri and SH Caldwell (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 1202-1219.
68. G Dhindsa, R Bhatia, M Dhindsa, et al. (2004) Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 50 140-144.
69. S Sam and A Dunaif (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14 365-370.
70. JD McGarry (1992) What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258 766-770.
71. K Almind, D Accili and CR Kahn (2004) Knockout mice as a tool to the understanding of diabetes. D LeRoith, SI Taylor, JM Olefsky,(Eds) Diabetes Mellitus: A Fundamental and Clinical Text Philadelphia: Lippincott 245-254.
72. MF White (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283 E413-E422.
73. GI Shulman (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106 171-176.
74. GM Reaven (1995) The fourth musketeer–from Alexandre Dumas to Claude Bernard. Diabetologia 38 3-13.
75. N Ruderman and M Prentki (2004) AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3 340-351.
76. NB Ruderman, AK Saha, D Vavvas, et al. (1999) Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276 E1-E18.
77. PJ Randle, PB Garland, CN Hales, et al. (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 785-789.
78. PJ Randle, EA Newsholme and PB Garland (1964) Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93 652-665.
79. PJ Randle, PB Garland, EA Newsholme, et al. (1965) The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 131 324-333.
80. PJ Randle (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14 263-283.
81. NB Ruderman, CJ Toews and E Shafrir (1969) Role of free fatty acids in glucose homeostasis. Arch Intern Med 123 299-313.
82. G Boden, F Jadali, J White, et al. (1991) Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88 960-966.
83. M Roden, TB Price, G Perseghin, et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97 2859-2865.
84. A Dresner, D Laurent, M Marcucci, et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 253-259.
85. G Boden and GI Shulman (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32(Suppl 3), 14-23.
86. BA Ellis, A Poynten, AJ Lowy, et al. (2000) Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 279 E554-E560.
87. ME Griffin, MJ Marcucci, GW Cline, et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48 1270-1274.
88. SI Itani, NB Ruderman, F Schmieder, et al. (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51 2005-2011.
89. G Boden, P She, M Mozzoli, et al. (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 54 3458-3465.
90. TK Lam, G van de Werve and A Giacca (2003) Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol 284 E281-E290.
91. VT Samuel, ZX Liu, X Qu, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 32345-32353.
92. SE Shoelson, J Lee and AB Goldfine (2006) Inflammation and insulin resistance. J Clin Invest 116 1793-1801.
93. R Considine, MR Nyce, LE Allen, et al. (1995) Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest 95 2938-2944.
94. RN Cortright, JL Azevedo Jr, Q Zhou, et al. (2000) Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol Endocrinol Metab 278 E553-E562.
95. G Boden (2004) Free fatty acids as a target for therapy. Current Opinions in Endocrinology and Diabetes
96. G Reaven (2004) Insulin resistance and its consequences type 2 diabetes mellitus and the insulin resistance syndrome. D Leroith, SI Taylor, JM Olefsky,(Eds) Diabetes melliltus: a fundamental and clinical text Lippincott Williams & Wilkins 899-915.
97. V Puri, S Ranjit, S Konda, et al. (2008) Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A 105 7833-7838.
98. G Perseghin, S Ghosh, K Gerow, et al. (1997) Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46 1001-1009.
99. JD McGarry (2002) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 7-18.
100. SJ Heydrick, NB Ruderman, TG Kurowski, et al. (1991) Enhanced stimulation of diacylglycerol and lipid synthesis by insulin in denervated muscle. Altered protein kinase C activity and possible link to insulin resistance. Diabetes 40 1707-1711.
101. AK Saha, TG Kurowski, JR Colca, et al. (1994) Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 267 E95-E101.
102. RL Dobbins, LS Szczepaniak, B Bentley, et al. (2001) Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 50 123-130.
103. L Abu-Elheiga, MM Matzuk, KAH Abo-Hashema, et al. (2001) Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291 2613-2616.
104. CS Choi, DB Savage, L Abu-Elheiga, et al. (2007) Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A 104 16480-16485.
105. HJ Harwood Jr, SF Petras, LD Shelly, et al. (2003) Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 278 37099-37111.
106. DB Savage, CS Choi, VT Samuel, et al. (2006) Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116 817-824.
107. E Ravussin and BA Swinburn (1996) Energy expenditure and obesity. Diab Rev 4 403-422.
108. NB Ruderman, AK Saha and EW Kraegen (2003) Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 144 5166-5171.
109. GJ Etgen and BA Oldham (2000) Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49 684-688.
110. J Faldt, I Wernstedt, SM Fitzgerald, et al. (2004) Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 145 2680-2686.
111. M Kelly, C Keller, PR Avilucea, et al. (2004) AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320 449-454.
112. X Yu, S McCorkle, M Wang, et al. (2004) Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 47 2012-2021.
113. DE Kelley, J He, EV Menshikova, et al. (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51 2944-2950.
114. KF Petersen (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300 1140-1142.
115. K Morino, KF Petersen, S Dufour, et al. (2005) Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115 3587-3593.
116. ME Patti, AJ Butte, S Crunkhorn, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100 8466-8471.
117. VK Mootha, CM Lindgren, KF Eriksson, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 34 267-273.
118. B Nyholm, A Mengel, S Nielsen, et al. (1996) Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism. Diabetologia 39 813-822.
119. H Park, VK Kaushik, S Constant, et al. (2002) Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 277 32571-32577.
120. NB Ruderman, JM Cacicedo, S Itani, et al. (2003) Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 31 202-206.
121. MS Gauthier, H Miyoshi, SC Souza, et al. (2008) AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J Biol Chem 283 16514-16524.
122. M Christ-Crain, B Kola, F Lolli, et al. (2008) AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 22 1672-1683.
123. GR Steinberg, BJ Michell, BJ van Denderen, et al. (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4 465-474.
124. RR Banerjee, SM Rangwala, JS Shapiro, et al. (2004) Regulation of fasted blood glucose by resistin. Science 303 1195-1198.
125. R Bergeron, JM Ren, KS Cadman, et al. (2001) Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 281 E1340-E1346.
126. S Jager, C Handschin, J St-Pierre, et al. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104 12017-12022.
127. M Suwa, H Nakano and S Kumagai (2003) Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J Appl Physiol 95 960-968.
128. H Zong, JM Ren, LH Young, et al. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A 99 15983-15987.
129. Z Wu, P Puigserver, U Andersson, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 115-124.
130. J Ek, G Andersen, SA Urhammer, et al. (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44 2220-2226.
131. K Hara, K Tobe, T Okada, et al. (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia 45 740-743.
132. KF Eriksson and F Lindgarde (1990) Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases. Diabetologia 33 526-531.
133. SH Schneider, LF Amorosa, AK Khachadurian, et al. (1984) Studies on the mechanism of improved glucose control during regular exercise in type 2 (non-insulin-dependent) diabetes. Diabetologia 26 355-360.
134. SH Schneider, AK Khachadurian, LF Amorosa, et al. (1992) Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 15 1800-1810.
135. H Wu, SB Kanatous, FA Thurmond, et al. (2002) Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296 349-352.
136. C Saloranta and L Groop (1996) Interactions between glucose and FFA metabolism in man. Diab Metab Rev 12 15-36.
137. O Gavrilova, B Marcus-Samuels, D Graham, et al. (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105 271-278.
138. JK Kim, O Gavrilova, Y Chen, et al. (2000) Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275 8456-8460.
139. RH Unger (2003) Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144 5159-5165.
140. GS Hotamisligil (2006) Inflammation and metabolic disorders. Nature 444 860-867.
141. B Gustafson, A Hammarstedt, CX Andersson, et al. (2007) Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27 2276-2283.
142. MW Rajala and PE Scherer (2003) Minireview: The adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 3765-3773.
143. TS Tsao, E Tomas, HE Murrey, et al. (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278 50810-50817.
144. PE Scherer (2006) Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55 1537-1545.
145. RS Lindsay, T Funahashi, RL Hanson, et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 57-58.
146. T Pischon, CJ Girman, GS Hotamisligil, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 1730-1737.
147. N Maeda, I Shimomura, K Kishida, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 731-737.
148. Y Okamoto, S Kihara, N Ouchi, et al. (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 2767-2770.
149. T Yamauchi, J Kamon, H Waki, et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 2461-2468.
150. AS Yu and EB Keeffe (2002) Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2 11-19.
151. J Fruebis, TS Tsao, S Javorschi, et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98 2005-2010.
152. E Tomas, TS Tsao, AK Saha, et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99 16309-16313.
153. T Yamauchi, J Kamon, Y Minokoshi, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 1288-1295.
154. TP Combs, AH Berg, S Obici, et al. (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108 1875-1881.
155. T Kadowaki and T Yamauchi (2005) Adiponectin and adiponectin receptors. Endocr Rev 26 439-451.
156. N Kubota, Y Terauchi, T Kubota, et al. (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281 8748-8755.
157. AR Nawrocki, MW Rajala, E Tomas, et al. (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281 2654-2660.
158. Y Zhang, R Proenca, M Maffei, et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372 425-432.
159. DM Muoio, K Seefeld, LA Witters, et al. (1999) AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 338(Pt 3), 783-791.
160. JM Friedman and JL Halaas (1998) Leptin and the regulation of body weight in mammals. Nature 395 763-770.
161. Y Minokoshi, YB Kim, OD Peroni, et al. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 339-343.
162. Y Minokoshi, T Alquier, N Furukawa, et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 569-574.
163. RH Unger (2002) Lipotoxic diseases. Annu Rev Med 53 319-336.
164. RH Unger and L Orci (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15 312-321.
165. M Higa, YT Zhou, M Ravazzola, et al. (1999) Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 96 11513-11518.
166. R Pold, LS Jensen, N Jessen, et al. (2005) Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54 928-934.
167. TA Pearson, GA Mensah, RW Alexander, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 499-511.
168. P Libby (2002) Inflammation in atherosclerosis. Nature 420 868-874.
169. T Collins and MI Cybulsky (2001) NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107 255-264.
170. T Nishikawa, D Edelstein, XL Du, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 787-790.
171. B Hennig, P Meerarani, P Ramadass, et al. (2000) Fatty acid-mediated activation of vascular endothelial cells. Metabolism 49 1006-1013.
172. SM Haffner, AS Greenberg, WM Weston, et al. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 679-684.
173. JB Meigs, FB Hu, N Rifai, et al. (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 1978-1986.
174. HO Steinberg and AD Baron (2002) Vascular function, insulin resistance and fatty acids. Diabetologia 45 623-634.
175. K Esposito, A Pontillo, C Di Palo, et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 1799-1804.
176. O Hamdy, S Ledbury, C Mullooly, et al. (2003) Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26 2119-2125.
177. FB Hu (2008) Obesity and Cardiovascular Disease Obesity, Epidemiology. New York: Oxford University Press
178. JM Cacicedo, N Yagihashi, JF Keaney Jr, et al. (2004) AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 324 1204-1209.
179. D Kukidome, T Nishikawa, K Sonoda, et al. (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55 120-127.
180. Y Ido, D Carling and N Ruderman (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51 159-167.
181. W Sun, TS Lee, M Zhu, et al. (2006) Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114 2655-2662.
182. PM Ridker, E Danielson, FA Fonseca, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 2195-2207.
183. KF Petersen, S Dufour, D Befroy, et al. (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 603-608.
184. A Seppala-Lindroos, S Vehkavaara, AM Hakkinen, et al. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 3023-3028.
185. TK Lam, H Yoshii, CA Haber, et al. (2002) Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283 E682-E691.
186. VT Samuel, ZX Liu, A Wang, et al. (2007) Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117 739-745.
187. V Poitout and RP Robertson (2002) Minireview: secondary beta-cell failure in type 2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology 143 339-342.
188. W El-Assaad, J Buteau, ML Peyot, et al. (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144 4154-4163.
189. M Prentki, E Joly, W El-Assaad, et al. (2002) Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 51 S405-413.
190. RP Robertson, J Harmon, PO Tran, et al. (2003) Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52 581-587.
191. S Bakker, R Jzerman, T Teerlink, et al. (2000) Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 148 17-21.
192. FB Hu (2008) Metabolic consequence of obesity, Obesity, Epidemiology. New York: Oxford University Press
193. C Yu, Y Chen, GW Cline, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277 50230-50236.
194. DR Laybutt, C Schmitz-Peiffer, AK Saha, et al. (1999) Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 277 E1070-E1076.
195. C Schmitz-Peiffer, CL Browne, ND Oakes, et al. (1997) Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46 169-178.
196. RS Hundal, KF Petersen, AB Mayerson, et al. (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109 1321-1326.
197. M Yuan, N Konstantopoulos, J Lee, et al. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 293 1673-1677.
198. BB Kahn, T Alquier, D Carling, et al. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 15-25.
199. K Morino, S Neschen, S Bilz, et al. (2008) Muscle-specific IRS-1 Ser→Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes 57 2644-2651.
200. MS Brown and JL Goldstein (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7 95-96.
201. JL Evans, ID Goldfine, BA Maddux, et al. (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23 599-622.
202. S Jacob, J Machann, K Rett, et al. (1999) Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48 1113-1119.
203. M Krssak, K Falk Petersen, A Dresner, et al. (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42 113-116.
204. SF Kim, AS Huang, AM Snowman, et al. (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104 3456-3459.
205. BR Walker (2004) Is “Cushing's disease of the omentum” an affliction of mouse and men? Diabetologia 47 767-769.
206. DB Savage, GD Tan, CL Acerini, et al. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52 910-917.
207. M Hawkins, M Hu, J Yu, et al. (1999) Discordant effects of glucosamine on insulin-stimulated glucose metabolism and phosphatidylinositol 3-kinase activity. J Biol Chem 274 31312-31319.
208. DA McClain and ED Crook (1996) Hexosamines and insulin resistance. Diabetes 45 1003-1009.
209. ME Gregor, L Yang, E Fabbrini, et al. (2009) Endoplasmic reticulum stress is reduced in tissue of obese subjects after weight loss. Diabetes 58 693-700.
210. A Garg (2004) Acquired and inherited lipodystrophies. N Engl J Med 350 1220-1234.
211. EA Oral, V Simha, E Ruiz, et al. (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 570-578.
212. KF Petersen, EA Oral, S Dufour, et al. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109 1345-1350.
213. A Fleischman, SE Shoelson, R Bernier, et al. (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31 289-294.
214. SM Grundy, HB Brewer Jr, JI Cleeman, et al. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 433-438.
215. KL Cheal, F Abbasi, C Lamendola, et al. (2004) Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53 1195-1200.
216. PM McKeigue, T Pierpoint, JE Ferrie, et al. (1992) Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 35 785-791.
217. JD Brunzell and AF Ayyobi (2003) Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 115(Suppl 8A), 24S-28S.
218. B Isomaa, P Almgren, T Tuomi, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 683-689.
219. B Isomaa, M Henricsson, P Almgren, et al. (2001) The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44 1148-1154.
220. HM Lakka, DE Laaksonen, TA Lakka, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 2709-2716.
221. CM Alexander, PB Landsman, SM Teutsch, et al. (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52(5), 1210-1214.
222. N Sattar, A Gaw, O Scherbakova, et al. (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 414-419.
223. SM Grundy (2007) Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? Am J Med 120 S3-S8.
224. RM Green (2003) NASH–hepatic metabolism and not simply the metabolic syndrome. Hepatology 38 14-17.
225. G Marchesini, M Brizi, G Bianchi, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 1844-1850.
226. N Stefan, K Kantartzis and HU Haring (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29 939-960.
227. EA Roberts (2003) Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 5 253-259.
228. KF Petersen, S Dufour, DB Savage, et al. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104 12587-12594.
229. RS Legro, AR Kunselman, WC Dodson, et al. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 165-169.
230. CG Solomon, FB Hu, A Dunaif, et al. (2002) Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 2013-2017.
231. EE Calle and MJ Thun (2004) Obesity and cancer. Oncogene 23 6365-6378.
232. SA Hawley, J Boudeau, JL Reid, et al. (2003) Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2 28.
233. A Woods, SR Johnstone, K Dickerson, et al. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13 2004-2008.
234. Z Luo, AK Saha, X Xiang, et al. (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26 69-76.
235. H Motoshima, BJ Goldstein, M Igata, et al. (2006) AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574 63-71.
236. X Xiang, AK Saha, R Wen, et al. (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321 161-167.
237. AF Kramer and KI Erickson (2007) Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci 11 342-348.
238. GS Watson and S Craft (2006) Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J Neurol Sci 245 21-33.
239. D Morris (2006) Cushing's syndrome. LJ DeGroot,(Eds) Endocrinology ed 5 Philadelphia: Elsevier 429-464.
240. WW Seely and GH Williams (2001) The cardiovascular system and endocrine disease. KL Becker,(Eds) Principles and Practice of Endocrinology and Metabolism Philadelphia: Lippincott Williams & Wilkins 1857-1864.
241. J Sutinen, AM Hakkinen, J Westerbacka, et al. (2003) Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. Antivir Ther 8 199-207.
242. R Unger (2004) How adipocytes integrate surplus caloric intake with caloric storage: lessons from Morgan Spurlock and some French geese, Current Opinion in Endocrinology. Diabetes and Obesity 11 251-257.
243. EA Sims, E Danforth Jr, ES Horton, et al. (1973) Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res 29 457-496.
244. SM Grundy, B Hansen, SC Smith Jr, et al. (2004) Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109 551-556.
245. PJ Skerrett and JE Manson (2002) Exercise and diabetes prevention: reduction in risk of coronary heart disease in diabetes. N Ruderman, JT Devlin, SH Schneider, A Kriska,(Eds) Handbook of diabetes in exercise Alexandria VA: American Diabetes Association 155-182.
246. TJ Orchard, M Temprosa, R Goldberg, et al. (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 611-619.
247. J Lindstrom, P Ilanne-Parikka, M Peltonen, et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 1673-1679.
248. S Yusuf, H Gerstein, B Hoogwerf, et al. (2001) Ramipril and the development of diabetes. JAMA 286 1882-1885.
249. SJ Robins, HB Rubins, FH Faas, et al. (2003) Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 1513-1517.
250. UKPDS (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 854-865.
251. RR Holman, SK Paul, MA Bethel, et al. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 1577-1589.
252. SE Nissen and K Wolski (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 2457-2471.
253. AM Lincoff, K Wolski, SJ Nicholls, et al. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 1180-1188.
254. JA Dormandy, B Charbonnel, DJ Eckland, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366 1279-1289.
255. SE Nissen, SJ Nicholls, K Wolski, et al. (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 1561-1573.
256. DM Nathan, JB Buse, MB Davidson, et al. (2008) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29 1963-1972.
257. SM Grundy, JI Cleeman, CN Merz, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 227-239.
258. PM Ridker, N Rifai, M Clearfield, et al. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 1959-1965.
259. JL Rosenzweig, E Ferrannini, SM Grundy, et al. (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 3671-3689.
260. S Cook, M Weitzman, P Auinger, et al. (2003) Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 157 821-827.
261. GS Berenson, SR Srinivasan, W Bao, et al. (1998) Associations between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338 1650-1656.
262. A Must, PF Jacques, GE Dallal, et al. (1992) Long-term morbidity and mortality of overweight adolescents, A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 327 1350-1355.
263. J Steinberger and SR Daniels (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107 1448-1453.
264. DJ Barker, CN Hales, CH Fall, et al. (1993) Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36 62-67.
265. DI Phillips (1998) Birth weight and the future development of diabetes. A review of the evidence. Diabetes Care 21(Suppl 2), B150-B155.
266. SK Bhargava, HS Sachdev, CH Fall, et al. (2004) Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 350 865-875.
267. P Zimmet, KG Alberti and J Shaw (2001) Global and societal implications of the diabetes epidemic. Nature 414 782-787.
268. JV Neel (1962) Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 14 353-362.
269. Z Hu, SH Cha, S Chohnan, et al. (2003) Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A 100 12624-12629.
270. BE Kemp, D Stapleton, DJ Campbell, et al. (2003) AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31 162-168.
271. DG Hardie, JW Scott, DA Pan, et al. (2003) Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546 113-120.
272. MJ Sanders, PO Grondin, BD Hegarty, et al. (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 403 139-148.
273. MC Towler and DG Hardie (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 328-341.